VolitionRx Statistics
Total Valuation
VolitionRx has a market cap or net worth of $32.36 million. The enterprise value is $43.41 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VolitionRx has 130.99 million shares outstanding. The number of shares has increased by 20.49% in one year.
| Current Share Class | 130.99M |
| Shares Outstanding | 130.99M |
| Shares Change (YoY) | +20.49% |
| Shares Change (QoQ) | +5.42% |
| Owned by Insiders (%) | 6.98% |
| Owned by Institutions (%) | 13.08% |
| Float | 87.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.78 |
| Forward PS | 8.52 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 29.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.12
| Current Ratio | 0.12 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.02 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -148.34% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 456.48% |
| Weighted Average Cost of Capital (WACC) | 11.20% |
| Revenue Per Employee | $19,627 |
| Profits Per Employee | -$305,061 |
| Employee Count | 75 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.61% in the last 52 weeks. The beta is 1.30, so VolitionRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -56.61% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.50 |
| Relative Strength Index (RSI) | 42.16 |
| Average Volume (20 Days) | 2,615,981 |
Short Selling Information
The latest short interest is 1.12 million, so 0.85% of the outstanding shares have been sold short.
| Short Interest | 1.12M |
| Short Previous Month | 543,884 |
| Short % of Shares Out | 0.85% |
| Short % of Float | 1.28% |
| Short Ratio (days to cover) | 0.44 |
Income Statement
In the last 12 months, VolitionRx had revenue of $1.47 million and -$22.88 million in losses. Loss per share was -$0.23.
| Revenue | 1.47M |
| Gross Profit | 1.47M |
| Operating Income | -22.70M |
| Pretax Income | -23.06M |
| Net Income | -22.88M |
| EBITDA | -21.65M |
| EBIT | -22.70M |
| Loss Per Share | -$0.23 |
Full Income StatementBalance Sheet
The company has $199,407 in cash and $11.26 million in debt, with a net cash position of -$11.06 million or -$0.08 per share.
| Cash & Cash Equivalents | 199,407 |
| Total Debt | 11.26M |
| Net Cash | -11.06M |
| Net Cash Per Share | -$0.08 |
| Equity (Book Value) | -35.95M |
| Book Value Per Share | -0.32 |
| Working Capital | -10.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.62 million and capital expenditures -$151,192, giving a free cash flow of -$19.77 million.
| Operating Cash Flow | -19.62M |
| Capital Expenditures | -151,192 |
| Free Cash Flow | -19.77M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,542.22% |
| Pretax Margin | -1,566.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VolitionRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.49% |
| Shareholder Yield | -20.49% |
| Earnings Yield | -70.71% |
| FCF Yield | -61.12% |
Analyst Forecast
The average price target for VolitionRx is $2.50, which is 912.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.50 |
| Price Target Difference | 912.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 141.01% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
VolitionRx has an Altman Z-Score of -65.93 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -65.93 |
| Piotroski F-Score | 2 |
